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Abstract
Background: Heterogeneous disease trajectories of mild cognitive impairment (MCI) and dementia are frequently
encountered in clinical practice, but there is still insufficient knowledge to understand the reasons and mechanisms
causing this heterogeneity. In addition to correlates of the disorder, patient characteristics such as their health
status, social environment, comorbidities and frailty may contribute to variability in trajectories over time. The
current paper outlines the study design and the study population of and provides an overview of the data
collected in the Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment (4C-MCI cohort, n = 315)
and Dementia (4C-Dementia cohort, n = 331) Study.
Methods: The two complementary longitudinal cohorts part of the 4C study began enrolment in March 2010.
Participants were prospectively recruited from three collaborating Dutch Alzheimer Centers, with three annual
follow-up assessments after baseline. Extensive neuropsychological assessments, and detailed profiling of
comorbidities, health and frailty at each follow up were the key features of the 4C study. As such, the 4C study was
designed to study if and how patients’ comorbidities and frailty are associated with the course of MCI and
dementia measured with a comprehensive and multidimensional set of outcomes including cognition, daily
functioning, quality of life, behavioral disturbances, caregiver burden, institutionalization and death and whether the
effects of medical health and frailty differ between MCI and dementia stages of cognitive disorders.
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Conclusion: Sampled in a clinical setting, the 4C study complements population-based studies on
neurodegenerative disorders in terms of the type of assessment (e.g. comorbidity, frailty, and functional status were
repeatedly assessed). The 4C study complements available clinical cohorts of MCI and dementia patients, because
the exclusion criteria were kept to a minimum, to obtain a sample that is representative for the average patient
visiting a memory clinic.
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Background
Dementia is a syndrome of impaired cognitive function-
ing that interferes with living independently. It is a
global public health issue with numbers of people suffer-
ing from dementia estimated to increase from 46.8
million in 2015 to 74.7 million in 2030, and to 131.5
million in 2050 worldwide [1]. Mild cognitive impair-
ment (MCI) is a state of impaired cognitive performance
that does not significantly interfere with independent
living and is a risk factor for developing dementia. Both
in MCI and dementia, progression over time varies
tremendously among patients. Some patients with MCI
progress precipitately after the diagnosis, whereas a sub-
stantial proportion of patients does not develop demen-
tia even after a prolonged period of up to 10 years [2].
In the stage of a clinically manifest dementia syndrome,
studies have shown huge differences in rate of decline
over time, even within a well-characterized cohort of
persons with dementia of the Alzheimer type [3]. Under-
standing the causes leading to heterogeneous trajectories
is essential for healthcare professionals to deliver personal-
ized care and to maximally delay the progression of the
condition. However, current knowledge cannot explain
the phenotypical heterogeneity present in patients. Part of
the heterogeneity in dementia presentation might be
attributed to different etiologies, such as (the combination
of) Alzheimer’s or vascular pathology. To further increase
our understanding of the observed heterogeneity, a theor-
etical framework has been developed that posits dementia
as a multi-causal, complex and dynamic disorder with
involvement of many body systems/organs at different
levels, rather than a disease with a single pathology [4].
The majority of patients with MCI and dementia are aged
and may experience different levels of frailty and suffer
from a considerable number of comorbidities that may
affect clinical phenotype [5–9], How these patient charac-
teristics influence the development and prognosis of the
disorder is largely unknown. With the aim to evaluate the
impact of comorbidity and frailty on the course of MCI
and dementia, the Clinical Course of Cognition and
Comorbidity in Mild Cognitive Impairment and Dementia
Study (4C study) was conducted. The current paper
outlines the study design, the study population and an
overview of the data collected.
4C study research objectives
As part of the 4C study two complementary multicenter
longitudinal cohorts were sampled in the Netherlands,
with the following research objectives:
1. Explore heterogeneity in trajectories of progression
in multiple outcomes, survival and
institutionalization, as well as conversion rates
(MCI to dementia and back and between
different nosological subtypes) in persons with
newly diagnosed MCI and dementia;
2. Investigate whether comorbidity (number and
severity of chronic comorbidities and presence
of certain comorbidities) and frailty influenced
the course and outcome of MCI and dementia;
3. Investigate predictors of transitions (conversions,
institutionalization, death) as well as compare
outcome trajectories right before and after transitions.
4. Investigate predictors and outcome trajectories
of persons who did not convert from MCI to
dementia and who were not institutionalized
5. Develop prognostic rules for conversion and
individual decline in cognition, behavior, and
daily functioning, institutionalization and death.
These research objectives are studied both in the
separate samples of MCI and dementia as well as in the
combined sample to evaluate differences between these
stages of increasingly severe cognitive decline.
Construction and content
Study design and participants
The MCI and Dementia cohort of the 4C study were
similar in study design and implementation, but were
conducted in different disease stages. Both cohorts
aimed to enroll 300 participants at baseline, equally from
the three participating centres Alzheimer Center of the
VU University Medical Center Amsterdam, Alzheimer
Centre Limburg of the Maastricht University Medical
Center and Radboudumc Alzheimer Center, Radboud
university medical center. The departments hosting the
three memory clinics have a background in neurology
(Amsterdam), old age psychiatry (Maastricht) and geriat-
ric medicine (Nijmegen).
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The study base of this cohort study were all per-
sons referred to one of the three memory clinics by
their primary care physician or referring medical
specialist. The inclusion period ran from the March
2010 until May 2011. All consecutive referrals were
prospectively evaluated for study eligibility during
that period.
People with a new diagnosis of dementia made during
this memory clinic visit were eligible for the Dementia
cohort. Patients who had subjective cognitive decline or
objective cognitive impairments based on neuropsycho-
logical test results, but did not fulfill the diagnostic
criteria for dementia were eligible for the MCI cohort.
The exact eligibility criteria for the 4C–MCI and the
4C–Dementia cohorts are shown in Table 1. As such the
inclusion was broader than in most studies on MCI and
dementia since comorbidities were allowed, thus result-
ing in a patient sample that was more representative for
regular patient groups.
The clinician responsible for the care during the mem-
ory clinic visit asked whether patients would be willing
to consider participation in the 4C study. If so, they were
provided with written study information and a visit was
scheduled with a research assistant to obtain written
informed consent from the participant and an informant
and to complete the baseline assessments. In order to be
eligible, an informant had to be available and have
contact with the participant for at least once a week.
Almost all informants (about 90%) were either the par-
ticipant’s partner or offspring, often also serving in a
caregiving role. Not all participants had an informant
who provided care that qualified as informal caregiving.
However, if such a person could be identified, this
person was asked as the informant. As a rule the same
informant participated across the follow ups. In a
small number of cases exceptions were allowed to
minimize missings.
Data collection
The participants were scheduled to have three annual
follow-ups after the baseline measurement during visits
at the memory clinic. Annual follow-ups had to be con-
ducted within a 3 months’ time frame around the dates
of an annual schedule. The last assessment in the partic-
ipants who last entered the study was conducted in
August 2014. The flowcharts for both cohorts are shown
in Figs. 1 and 2.
A multidisciplinary team consisting of physicians,
neuropsychologists and research assistants collaborated
in the standardized collection of the baseline and follow
up data with the patient and the informant. As such, the
multidisciplinary team (led by a consultant neurologist,
psychiatrist or geriatrician respectively) responsible for
the clinical care of the participant at the memory was
also responsible for the research data collection. Data
were collected on demographics, syndrome diagnosis,
cognitive functioning, health conditions, functional abil-
ities, neuropsychiatric symptoms, quality of life, and care
resource use. An overview of the collected data per
measurement, who was the source of the information
and who collected the information is presented in
Table 2. The assessor scored the reliability of the partici-
pant’s answers.
In order to minimize the dropout rate, home visits
by a researcher trained as a psychologist were imple-
mented for those participants who were willing to
continue participation in the study but unable to visit
the memory clinics. In case participants needed an
institutionalization, they continued with the study.
The possibility to do the follow up assessment during
a home visit also facilitated this.
Syndrome diagnosis of MCI and dementia
Syndrome diagnoses were made at baseline and
reviewed at every follow-up visit based on clinical
Table 1 Eligibility criteria for the 4C Study
Inclusion criteria The 4C–MCI cohort The 4C–Dementia cohort
• Cognitive performance subjective cognitive complaints and/or objective
cognitive impairments
objective cognitive impairments
• Fulfil the DSM-IV diagnostic criteria for dementia [12] No Yes
• Clinical Dementia Rating (CDR) Scale [34] 0–0.5 0.5–2
• Mini Metal State Examination (MMSE) score [35] Not specified ≥10
• Age ≥ 55 years Not specified
Exclusion criteria (similar for both cohorts)
• The absence of a reliable informant (who has contact with the participant for at least once a week);
• If the participant was expected unable to have at least one follow-up based on clinical judgment of the physician responsible for the care of
the patient at the memory clinic;
• The presence of other neurological disorders that could cause cognitive impairment or affect cognitive performance, such as Parkinson’s
Disease, Huntington’s Disease, Normal Pressure Hydrocephalus (NPH), Korsakov’s syndrome, and a medical history of brain tumour, encephalitis
or epilepsy. However, participants suffering from other cerebrovascular or psychiatric disorders were included in the studies.
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assessment by the physician and the multidisciplinary
team. For the minority of cases in whom the follow up
assessments were operationalized as a home visit, the
diagnosis review was determined by a physician from
the research data. The diagnosis of MCI was based on
Petersen criteria [10] and was operationalized as a z-
score lower than -1.5 SD (Dutch norm) on any of the
cognitive tests (see below). Subjects with cognitive
complaints without such a verified impairment on
cognitive tests were categorized as subjective cognitive
decline (SCD) [11]. The diagnosis of dementia was
based on DSM-IV criteria [12]. Nosological dementia
diagnoses were made according to standardized clin-
ical criteria for AD (NINCDS-ADRDA criteria [13]),
vascular dementia (NINDS-AIREN criteria [14]), fron-
totemporal dementia [15], and dementia with Lewy
bodies [16].
Cognitive assessment
Data about the self-reported onset (gradual or sudden),
course (stable, fluctuating or progressively deteriorated)
and duration of the cognitive complaints were collected.
In addition, patients were asked whether they had no-
ticed a change in four cognitive functions (memory,
concentration, mental capacity, and vitality) during the
last year [17]. Change in each function was scored on a
7-point Likert scale ranging from -3 (very strong
decline) to +3 (very strong improvement). If the partici-
pant was unable to answer by himself, the informant
reported it based on daily contact and observation.
The neuropsychological assessment consisted of the
same standardized battery of cognitive tests as used in the
Dutch Parelsnoer Instituut (www.parelsnoer.org), covering
the following domains: global cognition, episodic memory,
implicit visual learning, working memory, word fluency,
Fig. 1 Flowchart of the 4C–MCI cohort
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information processing speed, attention, executive func-
tioning and visual perception (Table 3) [17].
Further assessments and questionnaires
Height, weight, and, waist circumference, systolic and
diastolic blood pressure of the participants were re-
corded. Smoking and drinking status, the type, quantity
and frequency of tobacco and alcohol consumption were
asked. The physician structurally reviewed the patient’s
personal medical history at baseline, and particularly
queried extrapyramidal symptoms, gait disturbances,
and family history. Newly diagnosed diseases were
updated at every follow-up visit, also recording any
taken medication and each hospitalization (Table 4).
The Cumulative Illness Rating Scale for Geriatrics
(CIRS-G) was used to further quantitatively measure
disease burden and reflects the number and severity of the
diseases [18]. Using CIRS-G, all diseases were classified
into 14 organ systems: cardiac (heart only), vascular,
hematologic, respiratory, ophthalmologic and otorhinolar-
yngologic, upper gastrointestinal, lower gastrointestinal,
hepatic and pancreatic, renal, genitourinary, musculoskel-
etal and tegumental, neurologic, endocrine/metabolic and
breast, and psychiatric. If a patient had multiple diseases
in a single category, the most severe one was appraised.
The severity of impairment was rated with a 0–4 grading
scale from no problem to extremely severe problem (e.g.
organ failure) resulting in a total score ranging from 0 to
56. The CIRS-G can be adapted as a measure of pure
physical functioning in the 4C studies by excluding the
psychiatric category, since this category includes cognition
related comorbidities. The total score runs from 0 to 52.
Fig. 2 Flowchart of the 4C–Dementia cohort
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Frailty was operationalized using the five physical cri-
teria developed by Fried (2001) [19]. To that aim, grip
strength (dominant hand, average of two measures) was
measured using a Jamar® hand dynamometer and gait
speed while walking at usual speed across 4.5 m (average
of two measures). Unintentional weight loss and fatigue
(two questions of Center for Epidemiologic Studies
Depression Scale (CES-D)) were evaluated using ques-
tionnaires. Impaired physical activity was evaluated by
Table 2 Contents of data collection in the 4C studies
Baseline 12 months 24 months 36 months Assessed by Source
Informed consent √ Research assistant Participant and informant
Demographics √ √ √ √ Research assistant Participant and informant
MMSE [35] √ √ √ √ Physician Participant
CDR [34] √ √ √ √ Physician Participant and informant
Subjective cognitive functioning [17] √ √ √ √ Physician Informant
Neuropsychological assessment √ √ √ √ Psychologist Participant
Physical examination & structural medical review √ √ √ √ Physician Participant and informant
Medications (prescribed & taken) √ √ √ √ Physician Participant and informant
Hospitalization (if any) √ √ √ Research assistant Participant and informant
Syndromal diagnoses √ √ √ √ Physician Participant and informant
Comorbidities (CIRS-G) [18] √ √ √ √ Physician Participant and informant
Frailty (Fried criteria + Frailty Index) [19, 20] √ √ √ √ Research assistant Participant and informant
DAD (disability assessment) [21] √ √ √ √ Research assistant Informant
GDS-15 (depression, self-reported) [22] √ √ √ √ Research assistant Participant
NPI (neuropsychiatric symptoms) [23] √ √ √ √ Research assistant Informant
Euroqol 5D [24] √ √ √ √ Research assistant Informant
Care resource use √ √ √ √ Research assistant Informant
Refusal or withdrawal data √ √ √ √ Research assistant Participant and informant
Institutionalization (outcome & date) √ √ √ Research assistant Participant and informant
Death (outcome & date) √ √ √ Research assistant Informant
Table 3 Standardized cognitive tests and the corresponding
domains
Cognitive domain(s) Neuropsychological tests
Global cognition Mini Mental State Examination
(MMSE) [35]
Episodic memory 15-Word Verbal Learning Test (VLT)
immediate recall (5 trails), delayed
recall and delayed recognition [36]
Implicit associative visual learning Visual Association Test (VAT), short
version [37]
Working memory Digit Span subtest (forwards and
backwards) of the Wechsler Adult
Intelligence Test (3rd Edition) [38]
Verbal word fluency/semantic
memory
60 s animal fluency [39]









Trail Making Test (TMT) parts
A & B [42]
Visual perception Visual Object and Space Perception
battery (VOSP, Optional) Subtests of
dot counting and incomplete
letters [43]
Table 4 Structural medical review of participant’s health conditions
Body systems Concerned diseases
Cardiovascular angina, myocardial infarction, angioplasty/stent,
coronary bypass surgery, carotid stenosis,
hypertension, heart failure, others
Cerebrovascular transient ischemic attack (TIA), cerebrovascular
accidents (infarction, bleeding), reversible
ischemic neurologic deficit (RIND), others
Endocrinal diabetes mellitus, hypothyroidism, hyperthyroidism,
obesity, others
Psychiatric depression, psychosis, delirium, others
Somatic chronic obstructive pulmonary disease (COPD),
kidney problems, liver problems, others
Medications the names, doses, frequencies and the indications
of the medications
Hospitalization the primary diagnosis, acute or routine medical
care, the treating department, the total number
of nights spent in the hospital
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asking whether the participant yes or no exercised,
performed household chores, did odd jobs around the
house or gardened. If they did any of these, this item
was scored as not impaired. If participants did not
engage in any of these activities they were asked to rate
the time per week engaged in biking or walking. Multi-
plying these estimates by 4 and 3.5 kcal/min respectively
and summing them resulted in the estimated weekly
energy expenditure related to biking and walking. If this
estimate was below 393 or 280 kcal/week for men and
women respectively, physical activity was scored as
impaired. A frailty index based on accumulated deficits
also was operationalized from the 4C data [20].
The Disability Assessment for Dementia (DAD) scale,
measuring both basic and instrumental activities of daily
living (ADL, IADL), was used to evaluate the severity of
impairment in everyday functioning through a structured
interview with the informant [21]. The participants’
abilities to perform ten different (I)ADL activities in the 2
weeks prior to the assessment were rated. The final DAD
score was converted to a percentage from 0 to 100, in
which a higher percentage indicates a higher level of daily
functioning.
The 4C study used the Geriatric Depression Scale
(GDS-15) to assess the presence and severity of depres-
sive symptoms in older persons [22]. The Neuropsychi-
atric Inventory (NPI) was used to characterize the
psychopathology of the patient through a structured
interview with the informant, assessing 12 common
neuropsychiatric symptoms [23]. A screening question
for each neuropsychiatric symptom was asked to con-
firm the presence of the symptom before rating the fre-
quency (1–4, rarely–very often), severity (1–3, mild–
severe), and burden (0–5, not at all-extremely) for the
informant. The total NPI score ranged from 1 to 144.
The EQ-5D was used to measure health-related quality
of life and results in a score of 0–100, where higher
scores indicate better functioning [24]. The EQ-5D was
rated by the patient and by the informant: for the situ-
ation of the patient and for the informant him-/herself.
Besides patient and disease related data, also data about
the patient’s care resource use was investigated by asses-
sing the number of visits to the general practitioner, home
care, day care, institutionalized care, hospital in- and out-
patient, emergency care, other professionals, informal
care, medical goods, and out-of-pocket expenditures using
an informant questionnaire.
Refusal or withdrawal, minimum but essential data
collected for research
The reasons for dropout were collected and categorized.
The attrition is shown in the flowchart of Figs. 1 and 2.
With their consent, the study investigators made efforts
to collect minimal but essential study data through a
telephone interview when the participant (or informant)
wanted to discontinue their full participation. Researchers
asked about the course of cognitive symptoms, functional
abilities in (I)ADLs (any help or assistance needed in
certain activities), and global severity of dementia (CDR).
If the participant had received a diagnosis of MCI or
dementia from another physician, the syndrome diagnosis
was documented. Despite the participant’s refusal to
participate in a particular follow-up assessment, some
patients agreed to be approached at the next follow up
and did return to fully participate in the studies, as shown
in Figs. 1 and 2.
Adaptations of study protocol and implementation
Some changes to the original research protocol were
made for better implementation and completion of the
studies. Based on the experiences of baseline interview,
an evaluation of the reliability of information provided
by the participant and the informant was added to the
follow up assessments.
As a default, the assessments were carried out in the
memory clinics. However, for some participants, it was
inconvenient to visit the memory clinic due to immobil-
ity or other physical conditions. Where possible, home
visits (to the patient’s house or nursing home) were
implemented in the follow-ups and carried out by a
well-trained researcher, to limit study attrition.
Utility and discussion
Results
In the MCI and dementia cohort, 315 and 331 partici-
pants were included respectively. Noticeably, more men
than women were recruited in the MCI cohort (Table 5),
consistently across the three centers, whereas more
women were recruited in the Dementia cohort, except in
Amsterdam. Participants in the MCI cohort were
5.2 years younger, and had better cognitive performance,
functional abilities, physical condition and quality of life,
but had higher depression scores on average than those
in the Dementia cohort at baseline (Table 6).
Of 315 participants in the 4C-MCI cohort, 90 (29%) had
subjective cognitive decline and 151 (48%) had amnestic
MCI. Of 331 participants in the 4C dementia cohort, 216
(65%) had probable or possible AD. The majority of the
participants experienced a progressive cognitive decline in
the phase before the baseline diagnosis, namely 68% in the
MCI cohort, and 89% in the Dementia cohort, starting at
about 3–3.5 years on average before entering in either
cohort. Episodic memory was the most severely impaired
cognitive domain among MCI patients, whereas among
dementia patients, multiple cognitive functions were
severely impaired, especially executive functioning, atten-
tion and information processing speed.
Liao et al. BMC Neurology  (2016) 16:242 Page 7 of 11
By quantitative measures of disease burden (CIRS-
G), vascular diseases were the most frequent and
most severe comorbid category in both cohorts. The
total CIRS-G score leaving out the category of
psychiatric illness was higher in the dementia than in
the MCI cohort. For the AD patients in the dementia
cohort, it was found that comorbidities were associ-
ated with cognitive performance; frailty was associ-
ated with functional abilities at baseline [25].
Comparing older and younger persons with dementia
contrasting persons from the 4c Dementia cohort
data with persons from the NeedYD cohort [26],
showed that younger persons had less comorbidity
and may more often have neurological comorbidities
than older persons with dementia [27]. Further stud-
ies into the relationship of cognitive decline with
comorbidity and frailty are underway. In addition to
the objectives described earlier, these will focus on
determinants of health-related quality of life and gait
speed and grip strength as predictors of cognitive
decline in the MCI cohort.
The most prevalent neuropsychiatric symptoms re-
ported by the informants in the MCI cohort were irrit-
ability (51%, average score 5.4 out of 12 in NPI),
apathy/indifference (44%, 5.3) and depression/dysphoria
(41%, 4.7). These neuropsychiatric symptoms were also
most common in the dementia cohort, with different
rankings: apathy/indifference (51%, 6.5), depression/
dysphoria (38%, 5.3), irritability (36%, 5.3). When it
occurred, agitation and aggression (mean 3.3; SD 1.13)
was most burdening for informants in the MCI cohort.
This was also the most burdening symptom in the
Dementia cohort (3.0 ± 1.3).
After 3 follow-ups, 23 subjects (23/90, 26%) classified
as SCD at baseline were reclassified as MCI, 23 subjects
(23/225, 10%) with MCI reverted to SCD, and 74
subjects (10 subjects with SCD at baseline and 64
subjects with MCI at baseline) progressed to different
types of dementia (Table 7). The annual incidence of
MCI subjects progressing to dementia was 11% (32/278)
in the first 12 months, 7% (18/260) between 12 and
24 months and 10% (24/236) between 24 and 36 months
of follow up. In the dementia cohort, 91 patients (27%)
received at least one different (nosological) diagnosis of
dementia during the follow-ups. Of these 91, three
participants were rediagnosed as MCI, and one partici-
pant went from dementia to MCI (12 m) and via again
dementia (24 m) to SCD (36 m). Thus, in 4 (1.2%) of
331 participants the dementia diagnosis was reconsid-
ered. 16 patients (5%) in the MCI cohort and 75 (23%)
in the Dementia cohort died during 36 months of
follow-up. Studies to develop and validate prognostic
rules from these data are underway.
What are the main strengths and weakness?
One of the main questions for the 4C study was whether
the interaction with health status would influence the
natural disease course of cognitive disorders, and
contribute to the heterogeneity of clinical outcomes.
Thus, including participants with comorbidity in the
study and getting reliable diagnoses of comorbidities
were essential strengths of our studies, leading to more
representative patient groups. Prospectively sampling
diverse participants with natural disease courses from
various routine clinical settings (neurology, geriatrics
and old age psychiatry departments) who were represen-
tative for the MCI and dementia patients regularly seen
in memory clinics was another strength. Finally, cogni-
tive functioning is a central feature of MCI and demen-
tia. In the 4C study, in addition to global measures of
cognition, a series of standardized and validated neuro-
psychological tests were available to detail how different
cognitive domains changed and to explore the effect of
comorbidities on cognitive functioning in different
domains over time. While some longitudinal studies
Table 5 Baseline demographic characteristics of the participants
in the 4C Study





(years, mean ± SD)
69.7 ± 8.5 74.9 ± 10.2
Female sex 111 (35) 182 (55)




126 (40.0) 142 (44.1)
Middle (high school/
vocational education)
78 (24.8) 90 (28.0)




244 (77.5) 202 (61.2)
Widow/widower 42 (13.3) 93 (28.2)
Single, divorced 29 (9.2) 35 (10.6)
Living situation
Alone, independently 59 (18.7) 100 (30.5)
With partner and/or children 242 (76.8) 205 (62.5)
Institutionalized living 9 (2.9) 21 (6.4)
Others 5 (1.6) 2 (0.6)
Informant’s relation with the participant
Partner 224 (71.1) 179 (54.4)
Offspring 60 (19.5) 115 (35.0)
Sibling 7 (2.2) 10 (3.0)
Other relative or acquaintance 23 (7.3) 25 (7.6)
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focusing on risk factor discovery for dementia onset
continue to follow persons who develop MCI and/or
dementia, dedicated follow up studies are indispensable
to understand the more advanced stages of cognitive
decline. As such, the 4C study complements other
population-based and clinical MCI and dementia follow
up cohorts. In general, population-based (e.g. [28] or
[6]) and clinical samples of MCI and dementia (e.g. [29]
or [30]) are complementary in that the population-based
Table 6 Baseline cognitive, physical and functional
characteristics and quality of life of the participants in the 4C
Study
Mean ± SD, unless stated differently 4C-MCI cohort
(n = 315)
4C-Dementia
cohort (n = 331)
Subclassification cognitive disorder, N (%)a
Subjective cognitive decline 90 (29) n.a.
Amnestic MCI 151 (48) n.a.




Vascular dementia or any dementia
diagnosis with a vascular component
n.a. 71 (21)
Any other dementia diagnosis
without a vascular component
n.a. 44 (13)
Self-reported duration of cognitive
problems (years)
3.3 ± 3.8 3.1 ± 2.6
Self-reported course of cognitive problems, N (%)
Progressive 213 (67.6) 285 (89.1)
Stable 40 (12.7) 14 (4.4)
Fluctuated 33 (10.5) 21 (6.6)
Cognitive functionsb
MMSE (range 0–30, lower is worse) 26.9 ± 2.6 21.9 ± 3.7
VLT immediate recall (z-score,
lower is worse)
−1.1 ± 1.2 −2.3 ± 1.1
VLT delayed recall (z-score, lower
is worse)
−1.2 ± 1.3 −2.4 ± 0.9
60 s animal fluency (z-score, lower
is worse)
−0.7 ± 0.8 −1.7 ± 0.9
TMT-A (z-score, lower is worse) −0.3 ± 1.4 −1.7 ± 1.9
TMT-B (z-score, lower is worse) −0.4 ± 1.3 −1.8 ± 1.4
SCWT card 1 + 2 (z-score, lower
is worse)
−1.2 ± 1.7 −2.8 ± 2.5
SCWT card 3 (z-score, lower
is worse)
−1.2 ± 2.4 −3.5 ± 3.2
Neuropsychiatric symptoms
GDS-15 (range 0–15, higher
is worse)
3.6 ± 2.8 3.1 ± 2.7
NPI (range 0–144, higher is worse) 14.5 ± 15.0 16.3 ± 16.3
BMI (kg/m2, mean ± SD) 26.2 ± 3.9 25.9 ± 4.3
DAD (range 0–100, lower is worse) 86.7 ± 15.7 70.8 ± 24.1
CIRS-G
Total score (range 0–52c, higher
is worse)
7.09 ± 4.87 7.48 ± 4.94
Severity index (total score/number
of categories endorsed, range 0–4,
higher is worse)
1.57 ± 0.51 1.63 ± 0.55
Comorbidity index (number of
categories with score ≥2, range
0–13, higher is worse)
2.25 ± 1.93 2.37 ± 1.90
CIRS-G category with score ≥2 (at least
moderate disability or morbidity/requires
“first line” therapy), N (%)
Table 6 Baseline cognitive, physical and functional
characteristics and quality of life of the participants in the 4C
Study (Continued)
Heart 92 (29.2) 90 (27.3)
Vascular 144 (45.7) 170 (51.5)
Hematopoietic 12 (3.8) 25 (7.6)
Respiratory 74 (23.5) 54 (16.4)
Eyes/ears/nose/throat 54 (17.1) 72 (21.8)
Upper gastrointestinal 48 (15.2) 43 (13.0)
Lower gastrointestinal 28 (8.9) 35 (10.6)
Liver 20 (6.3) 21 (6.4)
Renal 15 (4.8) 19 (5.8)
Genitourinary 57 (18.1) 75 (22.7)
Neuromuscular 40 (12.7) 70 (21.2)
Neurological 75 (23.8) 48 (14.6)
Endocrine 49 (15.6) 59 (17.9)
Frailty according Fried Criteria, N (%)
Not frail (≤1 of 5 criteria satisfied), 219 (74.7) 224 (68.9)
Pre-frail (2 of 5 criteria satisfied) 44 (15.0) 55 (16.9)
Frail (≥3 of 5 criteria satisfied) 30 (10.2) 46 (14.2)
EQ-5D (with Dutch weights) (range
0–1, lower is worse)
0.98 ± 0.06 0.81 ± 0.20
EQ-5D VAS (range 0–100, lower
is worse)
69.4 ± 15.6 67.5 ± 16.9
a3 (1% of 315) participants in the 4C MCI cohort with MCI could not be
classified as amnestic versus non-amnestic MCI due to missing 15-Word Verbal
Learning Test scores
bDespite the application of the Petersen criteria for definition of MCI, mean
cognitive scores on the different domains may be above -1.5 SD of the Dutch
norm scores, because people with SCD were included in the 4C MCI cohort,
but do not satisfy the MCI criteria, also MCI patients were not required to
score below -1.5 SD on all domains assessed
cthe range of the CIRS-G is 0–52 rather than 0–56, as the psychiatric domain
was left out of the scale to create a measure of purely physical comorbidity
Table 7 The incidence of MCI subjects progressing to dementia
within the study duration
Study time line Number of subjects %
MCI conversion to dementia In the cohort
1 year follow-up 32 278 11.5
2 year follow-up 18 260 6.9
3 year follow-up 24 236 10.1
Total 74 315 23.4
Liao et al. BMC Neurology  (2016) 16:242 Page 9 of 11
studies have the advantage of being systematically
sampled from well characterized base populations,
whereas the clinical samples are able to add more detail
in terms of frequency and type/comprehensiveness of
assessment. To maximize the combined value of these
data [31], initiatives such as IALSA [32] and COSMIC
[33] help to identify datasets as well as provide method-
ologies in their combined analyses.
Discerning typical disease trajectories based on long-
term observation and developing prediction models for
disease progression would be beneficial for patient care.
However, for frontotemporal dementia, dementia with
lewy bodies or other types of dementia, due to limited
cases, more effort should be made to include more pa-
tients in future studies to increase the power or combin-
ing the current samples with other studies.
Attrition was the biggest challenge for the 4C study,
although it is inevitable due to the nature of the disease
and the aged population (see Figs. 1 and 2). In the MCI
cohort, 225 of 315 (71%) participants completed all three
follow ups (209; 66%) or completed follow ups until the
endpoint of death (16; 5%). In the Dementia cohort, 207
of 331 (63%) participants completed all three follow ups
(142; 43%) or completed follow ups until the endpoint of
death (65; 20%). Another 10 participants died during the
36 months of follow up, but dropped out of the study
for one of the other reasons.
Conclusions
Sampled in a clinical setting, the 4C study database
complements population-based studies on neurodegen-
erative disorders in terms of the type of assessment (e.g.
comorbidity, frailty, and functional status were repeat-
edly assessed). The 4C study complements available
databases of clinical cohorts of MCI and dementia pa-
tients, because the exclusion criteria were kept to a
minimum, to obtain a sample that is representative for
the average patient visiting a memory clinic. Cognition,
functional abilities, resource use and quality of life were
the key outcome domains and their longitudinal changes
and dynamic relations will be further explored, also re-
lated to endpoints such as death and institutionalization.
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